Judith S Sebolt-Leopold

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer (2024)
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer 5 (8) (2024)
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer 5 (8) (2024)
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer 5 (8) (2024)
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer (2024)
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Edmund S Kopetz, Judith S Sebolt-Leopold
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature cancer (2024)
Monika Sharma, Ivana Barravecchia, Robert Teis, Jeanette Cruz, Rachel Mumby, Elizabeth K Ziemke, Carlos E Espinoza, Varunkumar Krishnamoorthy, Brian R Magnuson, Mats Ljungman, Carl J Koschmann, Joya Chandra, Christopher E Whitehead, Judith S Sebolt-Leopold, Stefanie Galban
Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. Molecular cancer therapeutics (2023)
Cara Abecunas, Christopher E Whitehead, Elizabeth K Ziemke, Douglas G Baumann, Christy L Frankowski-McGregor, Judith S Sebolt-Leopold, Mohammad Fallahi-Sichani
Loss of NF1 in melanoma confers sensitivity to SYK kinase inhibition. Cancer research (2022)